← Back to Search
Generation Of The Combined Prothrombin Activation Peptide (F1-2) During The Clotting Of Blood And Plasma.
D. Aronson, L. Stevan, A. Ball, B. Franza, J. S. Finlayson
Published 1977 · Medicine, Chemistry
Download PDFAnalyze on Scholarcy
We have investigated the pathway of prothrombin activation in blood and plasma. By means of a rapid purification procedure involving chromatography on DEAE-cellulose and hydroxyapatite, we demonstrated that the major prothrombin fragment in serum is that representing the amino-terminal half of prothrombin (i.e. F1-2). The F1-2 isolated was characterized by its size, amino acid and antigenic compositions, amino-terminal residue, and the peptides (designated F1 and F2, respectively) it yielded upon hydrolysis by thrombin. Measurements by the isotope dilution technique showed that F1-2 could account for the fate of at least 90% of the prothrombin originally present in plasma. By contrast, the serum concentration of the fragment representing the amino-terminal third of prothrombin (viz. F1) was less than 10% that of F1-2. These results demonstrated that the major route of prothrombin conversion in blood or plasma involves the removal of the combined activation fragment (F1-2) as a single peptide.
This paper references
Prothrombin fragmentation during coagulation of whole blood and plasma.
Ganrot Po (1969)
The conversion of prothrombin to thrombin. V. The activation of prothrombin by factor Xa in the presence of phospholipid.
C. Esmon (1974)
Activation Mechanism of Bovine Prothrombin to Thrombin by Activated Factor X
T. Morita (1973)
Studies on the chemical and enzymatic modification of glycoproteins. A general method for the tritiation of sialic acid-containing glycoproteins.
L. Van Lenten (1971)
Prothrombin activation induced by Ecarin - a prothrombin converting enzyme from Echis carinatus venom.
F. Kornalík (1975)
The mechanism of activation of bovine prothrombin by an activator isolated from Echis carinatus venon and characterization of the new active intermediates.
T. Morita (1976)
The specific assay of Prower-Stuart factor and factor VII.
K. Denson (1961)
Chromatographic analysis of the activation of human prothrombin with human thrombokinase.
D. Aronson (1966)
Activation of bovine prothrombin by an activator isolated from Echis carinatus venom.
T. Morita (1976)
The conversion of prothrombin to thrombin. II. Differentiation between thrombin- and factor Xa-catalyzed proteolyses.
C. Esmon (1974)
Mechanism of bovine prothrombin activation by an insoluble preparation of bovine factor X a (thrombokinase).
K. Stenn (1972)
K. Mann (1974)
A fluorescent end - group reagent for proteins and peptides
M. W. Mosesson (1973)
Estimation of prothrombin by the two - stage method
L. M. Tocantins (1961)
The essential covalent structure of human fibrinogen evinced by analysis of derivatives formed during plasmic hydrolysis.
M. Mosesson (1973)
Activation of human prothrombin by highly purified human factors V and X-a in presence of human antithrombin.
J. Rosenberg (1975)
Activation of fluorescein-labeled prothrombin.
D. Fass (1973)
The conversion of prothrombin to thrombin. III. The factor Xa-catalyzed activation of prothrombin.
C. Esmon (1974)
The reliability of molecular weight determinations by dodecyl sulfate-polyacrylamide gel electrophoresis.
K. Weber (1969)
Activation of human prothrombin by a procoagulant fraction from the venom of Echis carinatus. Identification of a high molecular weight intermediate with thrombin activity.
B. Franza (1975)
Nil 6 hn . 1969 . Prothrombin fragmentation during coagulation ofwhole blood and plasma
P. O. Ganrot (1970)
The activation of prothrombin. II. Partial reactions, physical and chemical characterization of the intermediates of activation.
C. Heldebrant (1973)
On the occurrence of polymorphic human prothrombin. Electrophoretic and chromatographic alterations of the molecule due to the action of thrombin.
G. F. Lanchantin (1968)
This paper is referenced by
Effect of dietary antioxidants on postprandial endothelial dysfunction induced by a high-fat meal in healthy subjects.
K. Esposito (2003)
THROMBIN SPECIFICITY *
J. Fenton (1981)
In vitro selection of structure-switching, self-reporting aptamers
S. S. Oh (2010)
The use of prothrombin activating snake venoms to measure human prethrombin 2: absence of prethrombin 2 in serum.
D. Aronson (1984)
Impact of rivaroxaban compared with warfarin on the coagulation status in Japanese patients with non-valvular atrial fibrillation: a preliminary analysis of the prothrombin fragment 1+2 levels.
K. Tajiri (2015)
The effects of bovine prothrombin fragment 1 and fragment 1.2 on prothrombin activation.
J. Govers-Riemslag (1985)
Inhibitory effect of calcium phosphate‐associated proteins on calcium oxalate crystallization: α2‐HS‐glycoprotein, prothrombin‐F1 and osteopontin
S. Nishio (2000)
Post-meal coagulation activation in diabetes mellitus: the effect of acarbose
A. Ceriello (2004)
Elevated Levels of Prothrombin Fragment 1 + 2 Indicate High Risk of Thrombosis
S. Ota (2008)
Cigarette smoking is associated with increased circulating proinflammatory and procoagulant markers in patients with chronic coronary artery disease: effects of aspirin treatment.
I. Ikonomidis (2005)
Zymogens and cofactors of blood coagulation.
Y. Nemerson (1980)
Vasodilator proteins: role in delayed cerebral vasospasm.
R. P. White (1986)
Thrombin‐induced thromboxane generation by neutrophils and lymphocytes: Dependence on enzymic site
R. Bizios (1987)
Melagatran, an oral active-site inhibitor of thrombin, prevents or delays formation of electrically induced occlusive thrombus in the canine coronary artery.
J. Mehta (1998)
Synergism between the contractile effect of epidermal growth factor and that of des‐Arg9‐bradykinin or of α.‐thrombin in rabbit aortic rings
D. Deblois (1992)
Human prothrombin fragments FI(αβ) and F2: Preparation and characterization of structural and biological properties☆
D. L. Aronson (1980)
Identification of a prothrombin derivative in human urine.
A. Bezeaud (1978)
Human neutrophil elastase alters human alpha-thrombin function: limited proteolysis near the gamma-cleavage site results in decreased fibrinogen clotting and platelet-stimulatory activity.
M. S. Brower (1987)
Thrombin contracts isolated bovine retinal small arteries in vitro.
N. B. Nyborg (1990)
INCREASED RISK OF THROMBOEMBOLISM AS A RESULT OF HIGH THROMBIN PRODUCTION IS ASSOCIATED WITH SHORT ACTIVATED PARTIAL THROMBOPLASTIN TIME IN CANCER PATIENTS ON AND AFTER CHEMOTHERAPY: A PROSPECTIVE STUDY IN A TERTIARY CARE HOSPITAL
Indranil Dhar (2014)
Can we reduce thrombin generation during coronary thrombolysis or coronary angioplasty
F. Andreotti (1995)
Relationship between fibrinogen protein and fibrinogen function in postmyocardial infarction patients.
E. Réganon (2001)
Eculizumab reduces complement activation, inflammation, endothelial damage, thrombosis, and renal injury markers in aHUS.
R. Cofiell (2015)
APPROACHES TO THE STUDY OF PROTHROMBIN CONFORMATION AND ACTIVATION IN BIOLOGICAL FLUIDS *
B. Furie (1981)
Heparin secretion by peritoneal mast cells stimulated by α-thrombin in rats
B. Umarova (2004)
Development and characterisation of a compact device for rapid real-time-on-chip detection of thrombin activity in human serum using bioluminescence resonance energy transfer (BRET).
Felix Weihs (2020)
Factor V leiden increases plasma F1+2 levels both in normal and deep venous thrombosis subjects.
F. Mercuri (2000)
Edoxaban versus enoxaparin for the prevention of venous thromboembolism after total knee or hip arthroplasty: pooled analysis of coagulation biomarkers and primary efficacy and safety endpoints from two phase 3 trials
Y. Kawai (2016)
Isolation and partial characterization of crystal matrix protein as a potent inhibitor of calcium oxalate crystal aggregation: evidence of activation peptide of human prothrombin
K. Suzuki (2004)
Markers of activated coagulation and their usefulness in the clinical laboratory.
A. Tripodi (1996)
Craig M. Jackson (1978)
[Factors influencing thrombin generation measured as thrombin-antithrombin complexes levels and using calibrated automated thrombogram in patients with advanced coronary artery disease].
E. Stepien (2007)See more